Fulgent Genetics (FLGT)
(Delayed Data from NSDQ)
$20.10 USD
+0.07 (0.35%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $20.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$20.10 USD
+0.07 (0.35%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $20.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Zacks News
Privia Health (PRVA) Misses Q4 Earnings Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of -60% and 3.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 300% and 1.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics, Inc. (FLGT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of -21.88% and 31.46%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Olink Holding AB (publ) Sponsored ADR (OLK): Can Its 66.0% Jump Turn into More Strength?
by Zacks Equity Research
Olink Holding AB (publ) Sponsored ADR (OLK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Fulgent Genetics, Inc. (FLGT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 75.76% and 8.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Fulgent Genetics, Inc. (FLGT) and Masimo (MASI) have performed compared to their sector so far this year.
Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 51.11% and 6.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Nyxoah SA (NYXH): Can Its 10.2% Jump Turn into More Strength?
by Zacks Equity Research
Nyxoah SA (NYXH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Are Medical Stocks Lagging Fulgent Genetics (FLGT) This Year?
by Zacks Equity Research
Here is how Fulgent Genetics, Inc. (FLGT) and Harrow Health (HROW) have performed compared to their sector so far this year.
Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Fulgent Genetics, Inc. (FLGT) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
Is Fulgent Genetics (FLGT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Fulgent Genetics, Inc. (FLGT) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
Fulgent Genetics, Inc. (FLGT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 14.29% and 13.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics, Inc. (FLGT) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 88.24% and 1.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics, Inc. (FLGT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 6.85% and 2.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Fulgent Genetics, Inc. (FLGT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Fulgent Genetics, Inc. (FLGT) closed at $58, marking a -1.46% move from the previous day.
Fulgent Genetics, Inc. (FLGT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Fulgent Genetics, Inc. (FLGT) closed at $58.31, marking a +0.4% move from the previous day.
Fulgent Genetics, Inc. (FLGT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) closed the most recent trading day at $54.65, moving -0.35% from the previous trading session.
Fulgent Genetics, Inc. (FLGT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) closed the most recent trading day at $49.73, moving -0.4% from the previous trading session.
Fulgent Genetics, Inc. (FLGT) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Fulgent Genetics, Inc. (FLGT) delivered earnings and revenue surprises of 14.12% and 6.58%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Computer Programs and Systems (CPSI) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Analysts Estimate Fullgent Genetics (FLGT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Fullgent Genetics (FLGT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fulgent Genetics (FLGT) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Strategic investments and expanding operations in China are likely to have contributed to Fulgent Genetics' (FLGT) first-quarter performance.
Fullgent Genetics (FLGT) Stock Moves -1.28%: What You Should Know
by Zacks Equity Research
Fullgent Genetics (FLGT) closed at $56.44 in the latest trading session, marking a -1.28% move from the prior day.
Fullgent Genetics (FLGT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Fullgent Genetics (FLGT) closed at $61.50 in the latest trading session, marking a +0.87% move from the prior day.
Is Fulgent Genetics (FLGT) a Suitable Value Investor Stock?
by Zacks Equity Research
Let's see if Fulgent Genetics (FLGT) stock is a good choice for value-oriented investors right now from multiple angles.